Zynex, Inc. (NASDAQ:ZYXI) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC cut its position in Zynex, Inc. (NASDAQ:ZYXI) by 1.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 230,678 shares of the company’s stock after selling 2,911 shares during the period. Rice Hall James & Associates LLC’s holdings in Zynex were worth $1,882,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ZYXI. Principal Financial Group Inc. increased its holdings in shares of Zynex by 56.4% in the first quarter. Principal Financial Group Inc. now owns 17,679 shares of the company’s stock valued at $219,000 after purchasing an additional 6,378 shares during the period. LSV Asset Management grew its holdings in Zynex by 45.1% during the first quarter. LSV Asset Management now owns 108,935 shares of the company’s stock worth $1,348,000 after acquiring an additional 33,840 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in Zynex during the first quarter worth about $137,000. Vanguard Group Inc. grew its holdings in Zynex by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock worth $14,684,000 after acquiring an additional 6,097 shares during the period. Finally, BOKF NA acquired a new stake in Zynex during the first quarter worth about $246,000. 29.68% of the stock is owned by institutional investors and hedge funds.

Zynex Stock Performance

NASDAQ ZYXI opened at $8.76 on Friday. The company has a market cap of $279.01 million, a PE ratio of 58.40 and a beta of 0.53. The stock’s 50 day simple moving average is $8.11 and its 200-day simple moving average is $9.09. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Zynex (NASDAQ:ZYXI) last released its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. As a group, equities research analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZYXI. HC Wainwright increased their price target on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada lowered their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Insider Buying and Selling

In related news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the transaction, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 12,083 shares of company stock worth $100,006. 52.13% of the stock is owned by corporate insiders.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.